[Other] Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study |
|
This post will be closed automatically in 2026-06-10 00:20
Reward10points
|
10
The impact of pre-transplant extramedullary disease on the outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukaemia in children- on behalf of PDWP/EBMT
20
Aircraft Engine Controls: Design, System Analysis, and Health Monitoring
20
Drag reduction of turbulent boundary layer over sawtooth riblet surface with superhydrophobic coat
20
Capture-Intensified Electrocatalytic Reduction of Postcombustion CO2 in Transporting and Catalytic Channels of Covalent Organic Frameworks
20
On non-abelian extensions of Rota--Baxter algebras, dendriform algebras and Wells short exact sequence
